Skip to main content

Profile: Jiang-Jiang Qin

JiangJiang Qin
Jiang-Jiang Qin, Ph.D.
Senior Research Scientist
Department of Pharmacological and Pharmaceutical Sciences
Science and Research Building 2
3455 Cullen Blvd., Room 136
Houston, TX 77204-5037

713-743-7160
jqin@central.uh.edu

Education

Post-Doctoral Fellow, Cancer Biology, Molecular Pharmacology, Experimental Therapeutics & Nanomedicine, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo

Ph.D. Biomedical Engineering (Genetic Engineering Medicine and Natural Medicine), School of Pharmacy, Shanghai Jiao Tong University, Shanghai

B.S. Pharmacy, School of Pharmacy, Shanghai Jiao Tong University, Shanghai

Research Interests

  • Discovery and development of small molecule anticancer and anti-inflammatory drugs
  • Targeted delivery of nanoparticles in cancer
  • Natural product chemistry

Awards & Honors

  • Years of Service Award issued by Texas Tech University Health Sciences Center, 2017
  • Shanghai Outstanding Doctoral Dissertation Award issued by Shanghai Municipal Education Commission, 2012
  • Scholarship Award for Excellent Doctoral Student granted by Chinese Ministry of Education, 2010
  • Ruth Mulan Chu-Chao Scholarship granted by Shanghai Mulan Education Foundation, 2010
  • National Excellent Scholarship granted by Chinese Ministry of Education, 2009
  • Ruth Mulan Chu-Chao Scholarship granted by Shanghai Mulan Education Foundation, 2008
  • Honor of Excellent Student of Shanghai Jiao Tong University, 2007
  • Third Prize Scholarship of Shanghai Jiao Tong University, 2003

Selected Publications

Qin JJ, Wang W, and Zhang R. Novel natural product therapeutics targeting inflammation and cancer. Chin J Nat Med 2017; 15(6):401-416.

Qin JJ, Wang W, and Zhang R. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. Progress in Molecular Biology and Translational Science 2017. (In press)

Xue B, Wang W, Qin JJ, Nijampatnam B, Murugesan S, Kozlovskaya V, Zhang R, Velu SE, and Kharlampieva E. Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. Acta Biomaterialia 2017; 58: 386-398.

Qin JJ*, Wang W*, Sarkar S, and Zhang R. Oral delivery of anti-MDM2 inhibitor SP141 with FcRn-targeted nanoparticles to treat breast cancer and metastasis. Journal of Controlled Release 2016; 6(237):101-114. (*equal contribution)

Qin JJ, Sarkar S, Voruganti S, Wang W, Zhang R. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget 2016; 7(22):32566-32578.

Qin JJ, Sarkar S, Voruganti S, Wang W, Zhang R. Identification of Lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for cancer therapy. J Biomed Res 2016; 30(4):322-333.

Qin JJ, Voruganti S, Wang W, Wang H, Zhang W, and Zhang R. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget 2015; 6(32):33106-19.

Qin JJ*, Wang W*, Voruganti S, Wang H, Zhang W, and Zhang R. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget 2015; 6: 2623-2640. (*equal contribution)

Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev 2015; 35(6): 1220-1267.

Voruganti S*, Qin JJ*, Sarkar S, Nag S, Walbi IA, Wang S, Zhao Y, Wang W, and Zhang R. Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action. Oncotarget 2015; 6(25): 21379-94. (*equal contribution)

Voruganti S*, Xu F*, Qin JJ*, Guo Y, Sarkar S, Gao M, Zheng Z, Wang MH, Zhou J, Qian B, Zhang R, Wang W. RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Lett. 2015 369(2):386-95. (*equal contribution)

Nag S*, Qin JJ*, Voruganti S, Wang MH, Buolamwini JK, Wang W, and Zhang R. Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr 2015; 29: 654-663. (*equal contribution).

Yu JX, Voruganti S, Li DD, Qin JJ, Nag S, Xu S, Velu SE, Wang W, Zhang R. Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chin J Nat Med 2015;13(7): 554-560.

Qin JJ*, Nag S*, Wang W, Zhou J, Zhang WD, Wang H, Zhang R. NFAT as cancer target: Mission possible? BBA-Rev Cancer 2014; 1846: 297-311. (*equal contribution)

Wang W, Qin JJ, Voruganti S, Wang H, Buolamwini JK, and Zhang R. Experimental therapy of pancreatic cancer with SP141, a novel pyrido[b]indole MDM2 inhibitor: in vitro and in vivo activities and mechanism of action. Gastroenterology 2014; 147: 893-902.

Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Buolamwini JK, Zhang R. A novel pyrido[b]indole MDM2 inhibitor, SP-141, exerts potent therapeutic effects in breast cancer models. Nat Commun 2014; 5: 5086.

Nag S*, Qin JJ*, Buolamwini JK, Wang W, and Zhang R. Development and validation of a liquid chromatography-triple quadrupole mass spectrometry method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and its application to initial pharmacokinetic studies. J Chromatogr B 2014; 969: 235-240. (*equal contribution)

Wang W*, Cheng J*, Qin JJ*, Voruganti S, Nag S, Fan J, Gao Q, Zhang R. RYBP expression is associated with the survival of patients with hepatocellular carcinoma and regulates tumor cell growth and the response to chemotherapy in vitro and in vivo. Oncotarget 2014; 5 (22):11604-11619. (*equal contribution)

Qin JJ*, Jin HZ*, Huang Y, Zhang SD, Shan L, Voruganti S, Nag S, Wang W, Zhang WD, Zhang R. Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz. Eur J Med Chem 2013; 68: 473-481. (*equal contribution)

Ye J*, Qin JJ*, Su J, Lin S, Huang Y, Jin HZ, Zhang WD. Identification and structural characterization of dimeric sesquiterpene lactones in Inula japonica Thunb. by high‐performance liquid chromatography/electrospray ionization with multi‐stage mass spectrometry. Rapid Commun Mass Spectrom 2013; 27(19): 2159-2169. (*equal contribution)

Li X, Yang X, Liu Y, Gong N, Yao W, Chen P, Qin JJ, Jin H, Li J, Chu R, Shan L, Zhang R, Zhang W, Wang H. Japonicone A suppresses growth of Burkitt Lymphoma cells through its effect on NF-κB. Clin Cancer Res 2013; 19(11), 2917-2928.

Chen D, Wang W, Qin JJ, Wang MH, Murugesan S, Nadkarni DH, Velu SE, Wang H, Zhang R. Identification of the ZAK-MKK4-JNK-TGFβ Signaling Pathway as a Molecular Target for Novel Synthetic Iminoquinone Anticancer Compound BA-TPQ. Curr Cancer Drug Targets 2013; 13(6): 651-660.

Nag S, Qin JJ, Srivenugopal KS, Wang M, Zhang R. The MDM2-p53 pathway revisited. J Biomed Res 2013; 27(4): 254-271.

Qian B, Nag SA, Su Y, Qin JJ, Voruganti S, Zhang R, Cho WCS. miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets 2013; 13(5): 519-541.

Qin JJ, Nag SN, Voruganti S, Wang W, Zhang R. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. Curr Med Chem 2012; 19: 5705-5725.

Wang W, Zhang X, Qin JJ, Nag SA, Voruganti S, Wang MH, Wang H, Zhang R. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PloS One 2012; 7(7): e41586.

Nag SA, Qin JJ, Wang W, Wang MH, Wang H, Zhang R. Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol 2012; 3: 25.

Yang X, Wang W, Qin JJ, Wang MH, Sharma H, Buolamwini JK, Wang H, Zhang R. JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. PLoS One 2012; 7: e34303.

Rayburn E, Wang W, Li M, Zhang X, Xu H, Li H, Qin JJ, Jia L, Covey J, Lee M, Zhang R. Preclinical Pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemoth Pharma 2012; 69: 1423-1431.

Nag SA, Nadkarni DH, Qin JJ, Voruganti S, Nguyen T, Wang W, Wang H, Velu SE, Zhang R. Anticancer activity and molecular mechanisms of action of makaluvamines and analogues. Mol Cell Pharmacol 2012; 4(2): 69-81

Qin JJ, Huang Y, Wang D, Cheng XR, Zeng Q, Zhang SD, Hu ZL, Jin HZ, Zhang WD. Lineariifolianoids A-D, rare unsymmetrical sesquiterpenoid dimers comprised of xanthane and guaiane framework units from Inula lineariifolia. RSC Adv 2012; 2: 1307-1309.

Qin JJ, Zhu JX, Zeng Q, Cheng XR, Zhang SD, Jin HZ, Zhang WD. Sesquiterpene lactones from Inula hupehensis inhibit nitric oxide production in RAW264.7 macrophages. Planta Med 2012; 78: 1002-1009.

Hu ZL*, Qin JJ*, Zhang HH*, Wang D, Hua YP, Ding JP, Shan L, Jin HZ, Zhang JP, Zhang WD. Japonicone A antagonizes the activity of TNF-α by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1. Biochem Pharmacol 2012; 84(11): 1482-1491. (*equal contribution)

Qin JJ, Wang LY, Zhu JX, Jin H Z, Fu JJ, Liu XF, Li HL, Zhang WD. Neojaponicone A, a bioactive sesquiterpene lactone dimer with an unprecedented carbon skeleton from Inula japonica. Chem Commun 2011; 47: 1222-1224.

Qin JJ, Zhu JX, Zeng Q, Cheng XR, Zhu Y, Zhang SD, Shan L, Jin HZ, Zhang WD. Pseudoguaianolides and Guaianoildes from Inula hupehensis as Potential Anti-inflammatory Agents. J Nat Prod 2011; 74: 1881-1887.

Qin JJ, Zhu JX, Zhu Y, Yan L, Jin HZ, Zhang WD. Chemical constituents from the aerial parts of Inula japonica Thunb. Nat Prod Res Dev 2011; 23(6): 999-1001.

Qin JJ, Jin HZ, Zhu JX, Fu JJ, Zeng Q, Cheng XR, Zhu Y, Shan L, Zhang SD, Pan YX, Zhang WD. New sesquiterpenes from Inula japonica Thunb. with their inhibitory activities against LPS-induced NO production in RAW264.7 macrophages. Tetrahedron 2010; 66 (48): 9379-9388.

Qin JJ, Jin HZ, Zhu JX, Fu JJ, Hu XJ, Liu XH, Zhu Y, Yan SK, Zhang WD. Japonicones E-L, dimeric sesquiterpene lactones from Inula japonica Thunb. Planta Med 2010; 76(3): 278-283.

Qin JJ, Zhu JX, Zhu Y, Jin HZ, Lv YH, Zhang WD. Flavonoids from the aerial parts of Inula japonica. Chin J Nat Med 2010; 8(4): 257-259.

Qin JJ, Jin HZ, Fu JJ, Hu XJ, Wang Y, Yan SK, Zhang WD. Japonicones A-D, bioactive dimeric sesquiterpenes from Inula japonica Thunb. Bioorg Med Chem Lett 2009; 19(3): 710-713.

Qin JJ, Zhu JX, Zhang WD, Zhu Y, Fu JJ, Liu XH, Jin HZ. A new ent-kaurane type diterpenoid glycoside from Inula japonica Thunb. Arch Pharm Res 2009; 32(10): 1369-1372.

Qin JJ, Jin HZ, Fu JJ, Hu XJ, Zhu Y, Shen YH, Yan SK, Zhang WD. Anthranilic acid derivatives from Inula japonica. Chin Chem Lett 2008; 19: 556-558.

Qin JJ, Jin HZ, Fu JJ, Hu XJ, Shen YH, Yan SK, Zhang WD. Advances in studies on the pharmacological activities of Inula genus plants. Nat Prod Res Dev 2008; 20: 442-445. (Article in Chinese)

Presentations

Qin JJ, Wang W, Voruganti S, Zhang R, “Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy”, Amarillo Research Days, TTUHSC, Amarillo, TX; June 2016.

Qin JJ, Voruganti S, Wang W, Zhang R, “Identification of Lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for cancer therapy”, Amarillo Research Days, TTUHSC, Amarillo, TX; June 2016.

Qin JJ, Wang W, Zhang R, “Oral delivery of anti-MDM2 inhibitor SP141 with FcRn-targeted nanoparticles to treat breast cancer and metastasis”, Amarillo Research Days, TTUHSC, Amarillo, TX; June 2016.

Qin JJ, Wang W, Voruganti S, Zhang R, “Identifying a novel natural product MDM2 inhibitor for breast cancer therapy”, Amarillo Research Days, TTUHSC, Amarillo, TX; June 2015. (Outstanding Poster Award)

Qin JJ, Wang W, Cheng J, Voruganti S, Nag S, Gao Q, Zhang R, “RYBP as novel target for cancer gene therapy and biomarker for prognosis”, Amarillo Research Days, TTUHSC, Amarillo, TX; June 2015. (Outstanding Poster Award)

Voruganti S, Qin JJ, Sarkar S, Nag S, Walbi IA, Wang S, Zhao Y, Wang W, Zhang R, “Oral nano-delivery of natural anticancer ginsenosides”, Amarillo Research Days, TTUHSC, Amarillo, TX; June 2015.

Voruganti S, Qin JJ, Wang W, Zhang R, “Combination therapy with Adv-RYBP and chemotherapy in lung cancer”, Amarillo Research Days, TTUHSC, Amarillo, TX; June 2015.

Wang W, Qin JJ, Voruganti S, Zhang R, “Novel MDM2 inhibitor for breast cancer therapy: Where we are and where to go?” Amarillo Research Days, TTUHSC, Amarillo, TX; June 2015.

Qin JJ, Wang W, Voruganti S, Zhang R, “A novel MDM2 inhibitor suppresses breast cancer growth and metastasis”, AACR Annual Meeting, Philadelphia, PA, April 2015. Voruganti S, Qin JJ, Wang W, Zhang R, “The anticancer activity of Japonicone A is mediated by inhibiting NFAT1-MDM2 pathway”, AACR Annual Meeting, Philadelphia, PA, April 2015.

Wang W, Cheng J, Qin JJ, Voruganti S, Nag S, Fan J, Gao Q, Zhang R, “RYBP expression predicts survival of patients with hepatocellular carcinoma, and regulates response to chemotherapy”, AACR Annual Meeting, Philadelphia, PA, April 2015

Qin JJ, Voruganti S, Wang MH, Zhang W, and Zhang R, “Japonicone A, a Novel Dual Curriculum Vitae: Jiang-Jiang Qin, Ph.D. (Page 13 of 14) Inhibitor of NFAT1 and MDM2, for Breast Cancer Therapy”, Student Research Week, TTUHSC, Lubbock, TX; March 2014.

Voruganti S, Qin JJ, Wang W, Wang MH, Buolamwini JK, and Zhang R, “Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy”, Student Research Week, TTUHSC, Lubbock, TX; March 2014.

Nag SA, Qin JJ, Wang MH, Wang W, Buolamwini JK, Zhang R, “Ultra-performance liquidchromatography for rapid analysis of SP-141, a novel experimental anticancer agent, and an initial pharmacokinetics and biodistribution study", Student Research Week, TTUHSC, Lubbock, TX; March 2014.

Qin JJ, Voruganti S, Wang MH, Zhang WD, and Zhang R, “Japonicone A as a Novel Anti-Breast Cancer Therapeutic Agent by Targeting the NFAT1-MDM2-p53 Pathway”, AAPS Annual Meeting and Exposition, San Antonio, TX, November 2013

Voruganti S, Qin JJ, Wang W, Wang MH, Buolamwini JK, and Zhang R, “Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy”, AAPS Annual Meeting and Exposition, San Antonio, TX, November 2013

Nag SA, Qin JJ, Wang MH, Wang W, Buolamwini JK, and Zhang R, “Ultra-performance liquid-chromatography for rapid analysis of SP-141, a novel experimental anticancer agent, and an initial pharmacokinetics and biodistribution study”, AAPS Annual Meeting and Exposition, San Antonio, TX, November 2013

Patents

Dimeric sesquiterpene lactone compounds, preparation method and applications thereof Patent No.: CN101284835B; Grant Date: June 16, 2010 Inventors: Shan L, Zhang W, Li HL, Liu RH, Su J, Qin JJ, & Jin HZ

Compound bi-inulicin 4, preparation method and applications thereof Patent No.: CN101284833B; Grant Date: June 16, 2010 Inventors: Shan L, Zhang W, Li HL, Liu RH, Su J, Qin JJ, & Jin HZ

Bi-inulicin 1, preparation method and applications thereof Patent No.: CN101284834B; Grant Date: May 4, 2011 Inventors: Shan L, Zhang W, Li HL, Liu RH, Su J, Qin JJ, & Jin HZ

Application of japonicone A in preparation of tumor necrosis factor (TNF) inhibitor drugs Patent No.: CN102406637A; Publication Date: April 11, 2012 Inventors: Shan L, Zhang W, Li HL, Shen Y, Hu Z, Su J, Qin JJ, Zhao J & Jin HZ

Anti-inflammatory compound inula lineariifolia lactone A and preparation method and application thereof Patent No.: CN101830875A; Publication Date: September 15, 2010 Inventors: Zhang WD, Nie L, Qin JJ, Jin HZ, Huang Y.

Professional Memberships, Service & Appointments

Memberships

  • American Association of Pharmaceutical Scientists (AAPS), 2013-Present
  • American Association for Cancer Research (AACR),2015-Present
  • American Association for the Advancement of Science (AAAS),2015-Present

Editorial Appointments

Reviewer: Anti-Cancer Agents in Medicinal Chemistry; Archives of Pharmacal Research; Biochimie; Biomedicine & Pharmacotherapy; Cancer Translational Medicine; Cellular Physiology and Biochemistry; Chinese Journal of Natural Medicines; Current Cancer Drug Target; EBioMedicine; Experimental and Therapeutic Medicine; Fitoterapia; Frontiers in Pharmacology; GENE; International Journal of Biological Sciences; International Journal of Cancer; Journal of Medicinal Chemistry; Medicinal Chemistry; Medicinal Research Reviews; Phytochemistry Letters; Planta Medica